Vnitr Lek 2021, 67(4):E09-E12 | DOI: 10.36290/vnl.2021.062

Lymphangiomatosis - very rare disease of the lymphatic vessels

Zdeněk Král1, Marta Krejčí1, Ivana Červinková2, Luděk Pour1, Martin Štork, Martin Krejčí1, Viera Sandecká1, Zdeněk Adam1
1 Interní hematologická a onkologická klinika LF MU a FN Brno
2 Klinika dětské radiologie LF MU a FN Brno

Lymphangiomatosis is rare disease, we can find this entity in differential diagnosis of osteolytic leasions of bones of unknown origin. Typical sign for lymphangiomatosis is proliferation of lymphatic tissue with production of lymphangiomas in various organs and systems. Clinical manifestation of disease is variable, involvement of lungs and bone is typical. In our article we present recent classification of lymphatic tissue neoplasias, their clinical symptoms and treatment possibilities.

Keywords: lymphangiomatosis.

Published: June 29, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Král Z, Krejčí M, Červinková I, Pour L, Štork M, Krejčí M, et al.. Lymphangiomatosis - very rare disease of the lymphatic vessels. Vnitr Lek. 2021;67(4):E09-12. doi: 10.36290/vnl.2021.062.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Navrátilová Z, Štěrba J. Lymfangiomatóza skrota, břišní stěny a dolních končetin LYMPHO. Praha: AMCA. 2012: s. 26.
    2. Lukeš J, Dort V, Kohoutek V. Kostní systémová lymfangiomatóza. Československá pediatrie. 1973; 28: 417-419. Go to PubMed...
    3. Krásný J Baráková D, Chodounský Z et al. Lymfangiom orbitopalpebrální oblasti. Česká a slovenská oftalmologie. 2014; 70: 152-159. Go to PubMed...
    4. Rygl M, Šnajdauf J, Pýcha K et al. Abdominální lymfangiomy v dětském věku. Rozhledy v chirurgii. 2000; 79: 609-612. Go to PubMed...
    5. International Society for the Study of Vascular Anomalies: ISSVA classification for vascular anomalies (approved at the May 2018 General Assembly in Amsterdam, the Netherlands). http://issva.org/classification (last accessed June 2018).
    6. Trenor CC, Chaudry G. Complex lymphatic anomalies. Semin Pediatr Surg 2014; 23: 186-190. Go to original source... Go to PubMed...
    7. Blei F. Lymphangiomatosis: clinical overview. Lymphat Res Biol. 2011; 9: 185-190. Go to original source... Go to PubMed...
    8. Adams DM, Ricci KW. Vascular Anomalies: Diagnosis of Complicated Anomalies and New Medical Treatment Options. Hematol Oncol Clin North Am 2019; 33(3): 455-470. Go to original source... Go to PubMed...
    9. Ozeki M, Fukao T. Generalized lymphatic anomaly and Gorham-Stout disease: overview and recent insights. Adv Wound Care (New Rochelle) 2019; 8: 230-245. Go to original source... Go to PubMed...
    10. Greene AK, Goss JA. Vascular anomalies: from a clinicohistologic to a genetic framework. Plast Reconstr Surg 2018; 141: 709e-717e. Go to original source... Go to PubMed...
    11. Brouillard P, Boon L, Vikkula M. Genetics of lymphatic anomalies. J Clin Invest 2014; 124: 898-904. Go to original source... Go to PubMed...
    12. Osborn AJ, Dickie P, Neilson DE et al. Activating PIK3CA alleles and lymphangiogenic phenotype of lymphatic endothelial cells isolated from lymphatic malformations. Hum Mol Genet 2015; 24: 926-938. Go to original source... Go to PubMed...
    13. Boscolo E, Coma S, Luks VL et al. AKT hyper-phosphorylation associated with PI3K mutations in lymphatic endothelial cells from a patient with lymphatic malformation. Angiogenesis 2015; 18: 151-162. Go to original source... Go to PubMed...
    14. Manevitz-Mendelson E, Leichner GS, Barel O et al. Somatic NRAS mutation in patient with generalized lymphatic anomaly. Angiogenesis 2018; 21: 287-298. Go to original source... Go to PubMed...
    15. Yerganyan VV, Body JJ, De Saint Aubain N, Gebhart M. Gorham-Stout disease of the proximal fibula treated with radiotherapy and zoledronic acid. J Bone Oncol 2015; 16: 42-46. Go to original source... Go to PubMed...
    16. Hammer F, Kenn W, Wesselmann U et al. Gorham-Stout disease - stabilization during bisphosphonate treatment. J Bone Miner Res. 2005; 20: 350-353. Go to original source... Go to PubMed...
    17. Kato H, Ozeki M, Fukao T, Matsuo M. MR imaging findings of vertebral involvement in Gorham-Stout disease, generalized lymphatic anomaly, and kaposiform lymphangiomatosis. Jpn J Radiol 2017; 35: 606-612. Go to original source... Go to PubMed...
    18. Kuriyama DK, McElligott SC, Glaser DW et al. Treatment of Gorham-Stout disease with zoledronic acid and interferon-alpha: a case report and literature review. J Pediatr Hematol Oncol 2010; 32: 579-584. Go to original source... Go to PubMed...
    19. Ozeki M, Funato M, Kanda K et al. Clinical improvement of diffuse lymphangiomatosis with pegylated interferon alfa-2b therapy: case report and review of the literature. Pediatr Hematol Oncol 2007; 24: 513-524. Go to original source... Go to PubMed...
    20. Grunewald TG, Damke L, Maschan M et al. First report of effective and feasible treatment of multifocal lymphangiomatosis (Gorham-Stout) with bevacizumab in a child. Ann Oncol 2010; 21: 1733-1734. Go to original source... Go to PubMed...
    21. Ozeki M, Fukao T, Kondo N. Propranolol for intractable diffuse lymphangiomatosis. N Engl J Med 2011; 364: 1380-1382. Go to original source... Go to PubMed...
    22. Hammill AM, Wentzel M, Gupta A et al. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer 2011; 57: 1018-1024. Go to original source... Go to PubMed...
    23. Lackner H, Karastaneva A, Schwinger W et al. Sirolimus for the treatment of children with various complicated vascular anomalies. Eur J Pediatr 2015; 174: 1579-1584. Go to original source... Go to PubMed...
    24. Reinglas J, Ramphal R, Bromwich M. The successful management of diffuse lymphangiomatosis using sirolimus: a case report. Laryngoscope 2011; 121: 1851-1854. Go to original source... Go to PubMed...
    25. Adams DM, Trenor CC 3rd, Hammill AM, et al. Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies. Pediatrics 2016; 137: 1-10. Go to original source... Go to PubMed...
    26. Nadal M, Giraudeau B, Tavernier E et al. Efficacy and safety of mammalian target of rapamycin inhibitors in vascular anomalies: a systematic review. Acta Derm Venereo 2016; 96: 448-452. Go to original source... Go to PubMed...
    27. Itkin M. Interventional treatment of pulmonary lymphatic anomalies. Tech Vasc Interv Radiol 2016; 19: 299-304. Go to original source... Go to PubMed...
    28. Heyd R, Micke O, Surholt C et al. German Cooperative Group on Radiotherapy for Benign Diseases (GCG-BD). Radiation therapy for Gorham-Stout syndrome: results of a national patterns-of-care study and literature review. Int J Radiat Oncol Biol Phys 2011; 81: 179-185. Go to original source... Go to PubMed...
    29. Dunbar SF, Rosenberg A, Mankin H, Rosenthal D, Suit HD. Gorham's massive osteolysis: the role of radiation therapy and a review of the literature. Int J Radiat Oncol Biol Phys 1993; 26: 491-497. Go to original source... Go to PubMed...
    30. Müller-Wille R, Wildgruber M, Sadick M et al. Vascular Anomalies (Part II): Interventional therapy of peripheral vascular malformations. Rofo 2018; 190: 927-937. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.